7.77
전일 마감가:
$7.67
열려 있는:
$7.73
하루 거래량:
266.13K
Relative Volume:
0.67
시가총액:
$458.54M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-2.1057
EPS:
-3.69
순현금흐름:
$-134.48M
1주 성능:
-0.89%
1개월 성능:
-6.61%
6개월 성능:
-24.27%
1년 성능:
-58.02%
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CGEM
Cullinan Therapeutics Inc
|
7.77 | 462.67M | 0 | -153.16M | -134.48M | -3.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-11 | 재개 | Stifel | Buy |
2024-10-24 | 개시 | UBS | Buy |
2024-05-01 | 개시 | Stifel | Buy |
2024-04-15 | 개시 | William Blair | Outperform |
2024-02-15 | 개시 | Wedbush | Outperform |
2023-06-15 | 개시 | TD Cowen | Outperform |
2022-11-21 | 개시 | BTIG Research | Buy |
2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-02-02 | 개시 | Evercore ISI | Outperform |
2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
2021-02-02 | 개시 | SVB Leerink | Outperform |
2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionTop Growth Low Risk Stocks - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
Disc Medicine, Inc. Appoints Nadim Ahmed to Its Board of Directors - MarketScreener
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal - BioPharma Dive
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus
Cullinan Management Enters Global License Agreement with Genrix - TipRanks
Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com
Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune
Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - BioSpace
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus
Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - MarketScreener
ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):